Research guide for for men — mechanisms, protocols, and independent analysis from Compound Review.
Why GH Decline Matters for Men's Body Composition
Growth hormone secretion declines approximately 14% per decade after age 30 in men, contributing to increased visceral adiposity, reduced lean mass, impaired sleep architecture, and slower connective tissue repair. CJC-1295 addresses this by restoring GHRH signaling at the pituitary, amplifying GH pulse amplitude without disrupting the natural pulsatile pattern. This distinguishes it from exogenous GH, which suppresses endogenous production.
CJC-1295 Dosage Variants for Men
CJC-1295 with DAC is dosed at 1–2 mg subcutaneously once or twice weekly. CJC-1295 without DAC (Mod GRF 1-29) is dosed at 100 mcg 2–3× daily, typically before sleep and pre-workout, often combined with a GHRP like Ipamorelin at 100–200 mcg per injection. Men over 40 may benefit from the twice-weekly DAC variant for convenience and sustained GH elevation.
Clinical Evidence Summary
Human pharmacokinetic studies confirm that CJC-1295 with DAC produces sustained GH elevation for 6–8 days after a single injection. IGF-1 levels rise proportionally. No Phase 3 efficacy trials in age-related GH decline have been completed. The compound is not FDA-approved and is classified as a research chemical.